Heidi Brumbach
Corporate Officer/Principal chez Confirmit AS
Profil
Heidi Brumbach currently works as an Executive Vice President-Global Human Resources at Confirmit AS.
Currently, she holds the position of Vice President-People & Culture at Carmot Therapeutics, Inc.
Postes actifs de Heidi Brumbach
| Sociétés | Poste | Début |
|---|---|---|
Confirmit AS
 Confirmit AS Packaged SoftwareTechnology Services Confirmit AS engages in the development og online survey technologies for market research agencies. It offers software to collect customer and employee feedback, as well as market research applications for survey creation, data analysis, and reporting. The company was founded on October 7, 1996 and is headquartered in Oslo, Norway. | Corporate Officer/Principal | - |
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Responsable des Ressources Humaines | 01/01/2023 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Confirmit AS
Confirmit AS Packaged SoftwareTechnology Services Confirmit AS engages in the development og online survey technologies for market research agencies. It offers software to collect customer and employee feedback, as well as market research applications for survey creation, data analysis, and reporting. The company was founded on October 7, 1996 and is headquartered in Oslo, Norway. | Technology Services |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
